-
2024-513983-24-00
6
2021-10-29
Diabetic Macular Oedema
-
2024-514025-30-00
4
2021-03-25
Ocular conservative treatment for retinoblastoma
-
2024-510579-40-00
9
2020-10-07
Rhabdoyosarcoma
-
2023-505737-26-00
5
2020-07-22
Steroid refractory Acute Graft versus host Disease
-
2022-501050-11-01
10
2020-07-13
Acute Lymphoblastic Leukaemia
-
2024-517185-42-00
3
2020-05-04
Children and teenagers with refractory/relapsing solid tumor
-
2022-501454-11-00
5
2020-02-05
standard risk ALK-positive anaplastic large cell lymphoma (ALCL)
-
2023-507256-76-00
6
2020-01-14
Ulcerative colitis
-
2023-508926-91-00
5
2019-12-05
Stage IV childhood renal tumour with pulmonary +/- non-pulmonary
metas
-
2024-512321-84-00
5
2019-10-02
Patients after HSCT suffering from new or reactivated CMV or EBV or Ad
-
2024-514156-33-00
5
2019-08-20
Patients in remission for granulomatosis with polyangiitis (GPA,
Wegen
-
2024-510580-28-00
5
2019-06-05
Middle or low locally advanced resectable rectal carcinoma
-
2024-514780-26-00
4
2018-10-23
Patients ≤50 years old with high-risk osteosarcoma (defined as metasta
-
2023-504880-18-00
9
2018-04-18
Neuroblastoma (NBL)
-
2024-512827-36-00
4
2016-10-17
Penis carcinoma
-
2024-512222-28-00
10
2015-06-02
Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
-
2023-506027-29-00
5
2014-10-01
Children, adolescents and adults with newly diagnosed diffuse intrinsi
-
2024-517275-21-00
4
2012-02-20
Retinoblastoma
-
2025-521302-17-00
10
2026-05-26
Hihg risk of cholangiocarcinoma intra hépatic resectable
-
2024-516873-57-00
10
2026-01-13
Acute myeloid leukemia in adults aged 18 to 60
-
2023-505394-32-00
5
2025-02-06
chronic graft versus host disease
-
2024-513015-27-00
5
2025-01-09
Moderately to Severely Active Ulcerative Colitis (UC)
-
2023-510487-12-00
4
2024-11-29
Crohn's Disease
-
2023-508636-61-00
5
2024-10-24
Crohn’s Disease